$PMHS
Polomar Health Services, Inc.

2024 Q3 Form 10-Q Financial Statement

#000149315224032220 Filed on August 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue $9.849K
YoY Change
Cost Of Revenue $985.00
YoY Change
Gross Profit $8.864K
YoY Change
Gross Profit Margin 90.0%
Selling, General & Admin $268.0K $90.96K
YoY Change 279.33%
% of Gross Profit 3023.88%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $268.0K $20.12K $90.96K
YoY Change 279.35% -77.88% 563.54%
Operating Profit -$259.2K -$20.12K -$90.96K
YoY Change 266.8% -77.88% 563.54%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$12.16K
YoY Change -67.56%
Pretax Income -$90.96K
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$271.3K -$20.12K -$90.96K
YoY Change 150.9% -77.88% 563.54%
Net Earnings / Revenue -2754.93%
Basic Earnings Per Share -$0.01 $0.00 $0.00
Diluted Earnings Per Share -$0.01 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 109.1M shares 109.1M shares 107.8M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $28.02K
YoY Change
Cash & Equivalents $16.20K $294.00 $28.02K
Short-Term Investments
Other Short-Term Assets $2.210K
YoY Change
Inventory $139.9K
Prepaid Expenses
Receivables $20.00K
Other Receivables $80.00K
Total Short-Term Assets $156.1K $294.00 $130.2K
YoY Change 21.04% -99.77%
LONG-TERM ASSETS
Property, Plant & Equipment $87.73K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $19.04M
YoY Change
Total Long-Term Assets $19.13M $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $156.1K $294.00 $130.2K
Total Long-Term Assets $19.13M $0.00 $0.00
Total Assets $19.29M $294.00 $130.2K
YoY Change 14853.79% -99.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.670K
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $33.85K $6.360K
YoY Change 620.19%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $953.8K $103.0K $14.03K
YoY Change 6296.37% 634.11%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $23.62K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $953.8K $103.0K $14.03K
Total Long-Term Liabilities $23.62K $0.00
Total Liabilities $977.4K $103.0K $14.03K
YoY Change 6454.78% 634.11%
SHAREHOLDERS EQUITY
Retained Earnings -$2.192M -$1.487M -$1.163M
YoY Change 72.53% 27.94%
Common Stock $27.66K $109.1K $108.6K
YoY Change -74.66% 0.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.31M -$102.7K $116.2K
YoY Change
Total Liabilities & Shareholders Equity $19.29M $294.00 $130.2K
YoY Change 14853.79% -99.77%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$271.3K -$20.12K -$90.96K
YoY Change 150.9% -77.88% 563.54%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$171.4K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.110K
YoY Change
NET CHANGE
Cash From Operating Activities -171.4K
Cash From Investing Activities
Cash From Financing Activities 1.110K
Net Change In Cash -170.3K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$171.4K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Revenues
Revenues
usd
CY2024Q2 us-gaap Gross Profit
GrossProfit
usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
usd
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2000-09-14
us-gaap Revenues
Revenues
usd
CY2024Q2 us-gaap Cost Of Revenue
CostOfRevenue
usd
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
usd
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
295000000 shares
CY2023Q2 us-gaap Revenues
Revenues
usd
us-gaap Revenues
Revenues
usd
us-gaap Cost Of Revenue
CostOfRevenue
usd
us-gaap Cost Of Revenue
CostOfRevenue
usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
usd
us-gaap Gross Profit
GrossProfit
usd
us-gaap Gross Profit
GrossProfit
usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
294 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
244 usd
CY2024Q2 us-gaap Assets
Assets
294 usd
CY2023Q4 us-gaap Assets
Assets
244 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
22802 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
13782 usd
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
80171 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
102973 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13782 usd
CY2024Q2 us-gaap Liabilities
Liabilities
102973 usd
CY2023Q4 us-gaap Liabilities
Liabilities
13782 usd
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
500 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
500 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
295000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
109138049 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
109138049 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
109138049 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
109138049 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
109138 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
109138 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1275156 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1275156 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1487473 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1398333 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-102679 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-13539 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
294 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
244 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20116 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
90958 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
89140 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
180764 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
20116 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
90958 usd
us-gaap Operating Expenses
OperatingExpenses
89140 usd
us-gaap Operating Expenses
OperatingExpenses
180764 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-20116 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-90958 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-89140 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-180764 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-20116 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-90958 usd
us-gaap Net Income Loss
NetIncomeLoss
-89140 usd
us-gaap Net Income Loss
NetIncomeLoss
-180764 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109138049 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
108564879 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109138049 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
108564879 shares
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
207155 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-90958 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
116197 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-13539 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-69024 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-82563 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-82563 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-20116 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-102679 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-102679 usd
us-gaap Net Income Loss
NetIncomeLoss
-89140 usd
us-gaap Net Income Loss
NetIncomeLoss
-180764 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-10000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-3660 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
9019 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2655 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-80121 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-164449 usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
80171 usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
-80000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
110192 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1657 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
65000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
80171 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-33151 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
50 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-197600 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
244 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
225619 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
294 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28019 usd
CY2022Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
reverse split in which each shareholder was issued one common share in exchange for every two thousand common shares of their then-currently issued common stock
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
266157 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
266157 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
295000000 shares
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
75000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
295000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84B_eus-gaap--UseOfEstimates_zeo8m3ieRKxg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Use of estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
294 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1487473 usd
us-gaap Net Income Loss
NetIncomeLoss
-89140 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-80121 usd
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
295000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
295000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
295000000 shares
CY2023Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On June 3, 2023, the Board authorized the execution of a reverse split of the issued and outstanding shares of the Company’s common stock at a ratio of up to one post-split share per two thousand pre-split shares (1:2,000)
CY2023Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On March 2, 2023, FINRA approved a 1-for-2,000 reverse stock split of the Company’s common stock that was approved by the Board
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
109138049 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
109138049 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
109138049 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
109138049 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
trfe-20240630_cal.xml Edgar Link unprocessable
0001493152-24-032220-index-headers.html Edgar Link pending
0001493152-24-032220-index.html Edgar Link pending
0001493152-24-032220.txt Edgar Link pending
0001493152-24-032220-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
trfe-20240630.xsd Edgar Link pending
trfe-20240630_def.xml Edgar Link unprocessable
trfe-20240630_lab.xml Edgar Link unprocessable
trfe-20240630_pre.xml Edgar Link unprocessable